It inhibited tumor growth in organoid, xenograft and cell models by targeting N-myristoyltransferase 1 (NMT1), disrupting visinin-like protein-3 (VILIP3) myristoylation and NFκB/Bcl-2 signaling, suggesting NMT1 as a potential biomarker and therapeutic target in HCC. This evidence concerns the gene HPCAL1 and hepatocellular carcinoma.